NCT04081220进行中（未招募）2 期
An Investigator Initiated Phase 2 Trial of the LSD1 Inhibitor IMG-7289 in Essential Thrombocythemia (CTMS# 19-0078)
The University of Texas Health Science Center at San Antonio1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2020年4月9日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- The Proportion of Patients Who Achieve Complete Hematologic Remission at Week 24 Using ELN Response Criteria for ET (Barosi et al., 2013)
研究概览
简要总结
This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years.
- •Diagnosis of Essential Thrombocythemia per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms (Arber et al., 2016).
- •3. Patients who are intolerant or resistant to hydroxyurea per ELN (European Leukemia Net) criteria, or in the Investigator's judgment are not candidates for available approved therapy. The ELN definitions of resistance/intolerance to HU (hydroxyurea) requires the fulfillment of at least one of the following criteria:
- •Platelet count greater than 600 × 109/L after 3 months of at least 2 g/day of HU (2.5 g/day in patients with a body weight over 80 kg);
- •Platelet count greater than 400 × 109/L and leukocytes less than 2.5 × 109/L or hemoglobin (Hb) less than 100 g/L at any dose of HU;
- •Presence of leg ulcers or other unacceptable mucocutaneous manifestations at any dose of HU;
- •HU-related fever.
- •Requires treatment in order to lower platelet counts based on the Clinically Relevant IPSET (International Prognostic Score for Thrombosis in Essential Thrombocythemia) -Thrombosis Guidelines.
- •Platelet count >450 x 109/L pre-dose Day
- •Peripheral blast count <10% pre-dose Day
- •ANC (absolute neutrophil count) ≥0.5 x 109/L pre-dose Day
- •Fibrosis Score ≤ grade 2, as per a slightly modified version (Arber et al., 2016) of the European Consensus Criteria for Grading Myelofibrosis, (Thiele et al., 2005).
- •Life expectancy > 36 weeks.
- •Able to swallow capsules.
- •Amenable to spleen size determination, bone marrow evaluations, and peripheral blood sampling during the study.
- •Must have discontinued ET therapy at least 2 weeks (4 weeks for interferon) prior to study drug initiation.
- •Agrees to use an approved method of contraception from Screening until 28 days after last administration of the study drug. Acceptable methods of birth control include: birth control pills, depo-progesterone injections, a vaginal hormonal contraceptive ring, a barrier contraceptive such as a condom with spermicide cream or gel, diaphragms or cervical cap with spermicide cream or gel, or an intrauterine device (IUD).
- •If male, agrees not to donate sperm or father a child for at least one month after the last dose of the study medication.
排除标准
- •Greater than 3 separate transfusion episodes over the last 6 months and/or any transfusion over the last 4 weeks.
- •Eastern Cooperative Oncology Group (ECOG) questionnaire score of 3 or greater.
- •Currently pregnant or planning on being pregnant in the following 6 months or currently breastfeeding.
- •Currently residing outside the United States.
- •History of splenectomy.
- •Unresolved treatment related toxicities from prior therapies (unless resolved to ≤ Grade 1).
- •Uncontrolled active infection.
- •Known positive for HIV or infectious hepatitis, type A, B or C.
- •Current use of monoamine oxidase A and B inhibitors (MAOIs).
- •Evidence at the time of screening of increased risk of bleeding, including any of the following:
- •Activated partial thromboplastin time (aPTT) > 1.3 x the upper limit of normal
- •International normalized ratio (INR) >1.3 x the local upper limit of normal
- •Known Acquired Von Willebrand's disorder.
研究组 & 干预措施
IMG-7289
Experimental
干预措施: IMG-7289 (Drug)
结局指标
主要结局
The Proportion of Patients Who Achieve Complete Hematologic Remission at Week 24 Using ELN Response Criteria for ET (Barosi et al., 2013)
时间窗: 24 weeks
ELN criteria
次要结局
- Additional Therapy Period (ATP) Overall Symptom Burden(24 weeks to 48 weeks (may repeat))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
MDMA for AUD/PTSD ComorbidityAlcohol Use DisorderPost Traumatic Stress DisorderNCT05943665Carolina L Haass-Koffler22
进行中（未招募）
2 期
A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBCBreast CancerNCT04303741Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University46
已完成
2 期
MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSDPost Traumatic Stress DisorderCombat Stress DisordersNCT04264026VA Loma Linda Health Care System5
招募中
2 期
NCCH2006/MK010 Trial (FORTUNE Trial)Advanced or Recurrent Solid TumorsFGFR Gene AlterationsNCT04962867National Cancer Center, Japan75
Unknown
2 期
Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast CancerHER2-negative Breast CancerNCT04624711The First Affiliated Hospital with Nanjing Medical University40